ACTIVITY TITLE:
The Emerging Role of Novel GLP-1 RAs in the Management of T2DM: Assessing the Rationale and Evidence
ACTIVITY FORMAT:
Online webinar
PROGRAM DESCRIPTION
The recent advances in the management of type 2 diabetes mellitus (T2DM) have significantly changed the treatment
paradigm, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important part of this paradigm shift.
They have emerged as a highly effective option for T2DM, demonstrating robust glucose-lowering effects with the
additional benefits of low risk for hypoglycemia, weight loss, and improved cardiovascular outcomes. Furthermore,
new and novel GLP-1 RAs have the potential to increase the utility of this class. Given the rapid advances in this
field, clinicians may sometimes feel puzzled about how to best use the various T2DM agents, including existing and
novel GLP-1 RAs, to maximize patient outcomes.
In this webinar, experts will focus on the efficacy, safety, and the potential role existing and new GLP-1 RAs in
the management of T2DM. In addition, the activity will overview the current T2DM treatment landscape in order to
better convey ongoing treatment gaps and how emerging GLP-1 RAs can help address them.
ESTIMATED TIME TO COMPLETE: 60 minutes
RELEASE DATE: August 14, 2020
EXPIRATION DATE: August 14, 2021
EDUCATIONAL GRANT SUPPORT
This educational activity is supported by an educational grant from Novo Nordisk.
INTENDED AUDIENCE
This activity is designed for US-based endocrinologists, cardiologists, lipidologists, primary care physicians,
physician assistants, registered nurses, nurse practitioners, and pharmacists.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Review the recent guideline updates about the individualization of T2DM therapy
- Summarize the efficacy and safety of current T2DM pharmacologic therapy and the rationale for new and
emerging GLP-1 RAs in T2DM treatment
- Interpret the latest clinical trial data about the efficacy and safety of new and emerging GLP-1 RAs and
their potential role in T2DM management
FACULTY
Vanita R. Aroda, MD
- Director of Diabetes Clinical Research
- Brigham and Women's Hospital
- Boston, MA
Kathleen M. Dungan, MD, MPH
- Associate Professor, Division of Endocrinology, Diabetes & Metabolism
- Associate Director of Clinical Services, Division of Endocrinology, Diabetes & Metabolism
- The Ohio State University
- Columbus, OH
ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute
for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American
Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category
1
Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the
activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated
for 0.6 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
PHARMACIST ACCREDITATION STATEMENT
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.15 CEUs)
of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal
Activity Numbers (UAN): JA4008162-9999-20-2259-H01-P
Upon completing the post-survey and the activity evaluation form, transcript
information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are
in a position to control the content of this activity to disclose any real or apparent conflict of interest (COO
they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with high quality activities and related
materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a
commercial interest.
Faculty
Dr. Aroda discloses the following:
- Consulting Fees: Applied Therapeutics, Duke, Novo Nordisk, Sanofi
- Contracted Research: Applied Therapeutics, Premier/Fractyl, Novo Nordisk, Sanofi
Dr. Dungan discloses the following:
- Consulting Fees: Eli Lilly, Boehringer Ingelheim, Tolerion
- Contracted Research: Eli Lilly, Novo Nordisk, Sanofi Aventis, Abbott, Viacyte
Planners and Managers
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period August 14, 2020
through August 14, 2021, participants must read the learning objectives and faculty disclosures and study the
educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-survey and evaluation.
Upon completing, your certificate will be made available immediately.
For questions about the accreditation of this activity, please visit www.pimed.com.
Media: Internet
HARDWARE AND SOFTWARE REQUIREMENTS:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.
